Infinimmune
PrivateLast Round
Series A
Aug 11, 2026
Total Funding Raised
$87M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Infinimmune operates in Healthcare & Life Sciences and is based in Alameda, California. Its latest recorded funding round was a Series A round in August 2026.
Infinimmune is a biotechnology company that develops human-derived antibody medicines by discovering antigen-specific antibodies from human B cells via proprietary sequencing and AI-guided engineering platforms.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Infrastructure
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Infinimmune Comparables
Compare Infinimmune with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aureka Biotechnologies | 84% | |
| BigHat Biosciences | 83% | |
| Antiverse | 82% |
For institutional investors. Book with your work email.
Infinimmune Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Aug 11, 2026 | ||||
| Seed | Dec 6, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Infinimmune Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A |
| Playground Global | Seed, Series A |
| Wild Tree Ventures | Series A |
| Pear VC | Seed, Series A |
| Forge Life Science Partners | Series A |
| Everbright Biofund | Series A |
| Goldcrest Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 24, 2026
Grew 38% QoQ, from 16 to 22 employees.
- Aug 11, 2026
$75M round led by Playground Global and Regeneron Ventures.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- recognized_asOct 5, 2026
Fierce Biotech, a division of Forge, names Infinimmune a "Fierce 15" Biotech Company of 2026 in California on Oct 5th '26.
- is_developingAug 16, 2026
In California, Infinimmune develops human-derived antibody medicines using B-cell sequencing and computational modeling.
For institutional investors. Book with your work email.
Infinimmune Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Infinimmune's valuation, stock price, and market status.
Is Infinimmune a public or private company?
Infinimmune is a private company.
What is the current stock price of Infinimmune?
Infinimmune is a private company, so its shares have no public market price. Caplight tracks Infinimmune's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Infinimmune worth (valuation)?
Valuation information for Infinimmune is not publicly available.
Can I buy Infinimmune stock?
Infinimmune shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Infinimmune's last funding round?
Infinimmune's most recent funding round was Series A on August 11, 2026.
Who are the main investors in Infinimmune?
Key investors in Infinimmune include Playground Global.
Will Infinimmune IPO soon?
No public IPO plans have been announced for Infinimmune.
How can I track Infinimmune secondary market activity?
Caplight tracks bids, offers, and trades in Infinimmune's shares on secondary markets.